What it is
CJC-1295 is a modified analog of growth hormone-releasing hormone (GHRH). Ipamorelin is a ghrelin-receptor agonist described as a selective growth hormone secretagogue. Both have been studied for how they influence growth hormone release.
What the research says
- A human study reported that CJC-1295 produced prolonged increases in growth hormone and IGF-I levels [1].
- Ipamorelin was described in early research as a selective growth hormone secretagogue [2].
- A phase 2 trial of ipamorelin in people recovering from bowel surgery reported no significant difference from placebo in its efficacy analyses [3].
Regulatory status
CJC-1295 and ipamorelin are not FDA approved. Compounded versions are not FDA approved, and FDA has not established the combination as safe or effective. Where prescribed, compounded versions are prepared by state-licensed 503A compounding pharmacies.
Safety and side effects
FDA's compounding safety page lists ipamorelin acetate. It cites a published study that identified serious adverse events, including death, when ipamorelin was given intravenously, and notes possible immunogenicity and impurity risks for certain routes [4]. Raising growth hormone has effects throughout the body. A licensed healthcare provider should review your history, medications and labs before deciding anything.
Is it right for you?
Only a licensed healthcare provider can decide whether any treatment is appropriate for you.
Frequently asked questions
How are CJC-1295 and ipamorelin different?
They act on different receptors. CJC-1295 is a GHRH analog; ipamorelin acts on the ghrelin receptor [1][2].
Is CJC-1295 or ipamorelin approved by FDA?
No. Neither compound is approved by FDA. Compounded versions are not FDA approved.
Do I need a prescription for CJC-1295 / Ipamorelin?
Yes. Prescription only, requires evaluation by a licensed provider. A provider decides whether it is appropriate for you.
Sources
- Teichman SL, et al. Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295. J Clin Endocrinol Metab, 2006. https://pubmed.ncbi.nlm.nih.gov/16352683/
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol, 1998. https://pubmed.ncbi.nlm.nih.gov/9849822
- Beck DE, et al. Int J Colorectal Dis, 2014 (phase 2 ipamorelin trial; PubMed 25331030). https://pubmed.ncbi.nlm.nih.gov/25331030/
- FDA: Certain bulk drug substances for use in compounding that may present significant safety risks. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
CJC-1295 / Ipamorelin content on this page is for education. Compounded medications are not FDA approved. Prescription only, requires evaluation by a licensed provider. Educational content only, not medical advice.